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ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA
Serum levels of TNF-α and osteoprotegerin and bone mineral density in patients 
with Behçet’s Disease
Behçet hastalarında serum TNF- α ve osteoprotegerin düzeyi ve kemik kitle yoğunluğu
Ali Kutlucan1, Sevket Ercan Tunc2, Davut Baltacı3, Mehmet Sahin2, Mustafa Ozsahin4,
Recep Sütcü5, Fatih Ermis1, Harun Süslü6
ÖZET
Amaç: Behçet hastalığı (BH)’nın doğal seyri sırasında ya 
da kullanılan ilaçlara bağlı olarak osteoporoz gelişebilir. 
Çalışmanın amacı BH’nda osteoprotegerin ve tümor nek-
roz faktör (TNF-α) düzeyleri ve bunlar arasındaki korelas-
yonu araştırmaktır. 
Gereç ve yöntem: Çalışmaya, hasta grubu ve kontrol 
grubu olarak iki grup alındı. TNF-α, osteoprotegerin, oste-
okalsin, sedimantasyon, CRP, idrar kreatin ve deoksipri-
dinolin düzeyleri ile beraber kemik mineral dansitometrisi 
(KMD) ölçüldü ve iki grup karşılaştırıldı.
Bulgular: Çalışma grubuna 41 hasta, kontrol grubuna 36 
hasta alındı. Çalışma ve kontrol grubunun yaş ortalama-
sı sırasıyla 42.26±11.64 ve 41.66±70.99 bulundu. Vücut 
kitle indeksi yönünden iki grup arasında fark bulunmadı. 
TNF-α (p<0.001), deokspiridinolin (p<0.001) ve osteokal-
sin (p=0.041) düzeyleri kontrol grubundan önemli oranda 
yüksek bulundu. Osteoprotogerin düzeyi hasta grubunda 
düşüktü ancak anlamlı düzeyde değildi (p>0.05). İdrar de-
oxypyridinoline/ idrar kreatinin oranı hasta grubunda kon-
trol grubuna göre anlamlı yüksekti (p=0.03). Hasta grubun 
KMD ölçümü; L2-L4 hariç, kontrol grubuna göre anlamlı 
oranda  düşüktü  (sırasıyla  p<0.001,  p<0.001,  p=0.035, 
p<0.001, p=0.012, p<0.001, p<0.001 ve p=0.111). TNF-α 
ve osteoprotegerin arasında korelasyon saptanmadı.
Sonuç: Bu çalışmada TNF-α ve KMD arasında negatif 
korelasyon  saptandı  ve  TNF-α’nın,  BH’da  osteoporotik 
süreci etkilediği bulundu. Osteoprotogerin düzeyi düşük-
lüğü anlamlı değildi ve TNF-α ile korele değildi.
Anahtar kelimeler:  Behçet  hastalığı,  osteoprotegerin, 
TNF-α, osteokalsin
ABSTRACT
Objectives:  Osteoporosis  is  commonly  developed  due  to 
natural  course  of  Behçet’s  disease  (BD)  and  therapeutic 
agents. It was aimed to investigate levels of osteoprotegerin 
and TNF-α (tumor necrosis factor), and bone mineral density 
(BMD) and correlation between them in BD.
Materials and methods: The study included two groups 
as the study and the control group. Serum levels of TNF-α, 
osteoprotegerin, osteocalcine, erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), and urinary creatinine and 
deoxypyridinoline along with BMD level were evaluated and 
compared. Correlation between TNF-α and osteoprotegerin 
level was investigated. 
Results: The study enrolled 41 BD patients and 36 aged-
matched control subjects. Mean age was 42.26±11.64 and 
41.66±70.99, in the study and control groups, respectively. 
There  was  no  significant  difference  in  body  mass  index 
(BMI) of subjects between groups (p>0.05). Level of TNF-α 
(p<0.001),  deoxypyridinoline  (p<0.001)  and  osteocalcine 
(p=0.041) was significantly higher in the study group com-
pared  to  the  control  group.  Osteoprotegerin  was  lower  in 
BD patients, but the difference was not significant (p>0.05). 
Urinary deoxypyridinoline/ urinary creatinine ratio in patients 
with BD was significantly higher than those in control group 
(p=0.030). Patients had significantly lower BMD comparfed 
to the control group, except L2-L4 vertebral area (p<0.001, 
p<0.001, p=0.035, p<0.001, p=0.012, p<0.001, p<0.001 and 
p=0.111,  respectively).  No  correlation  was  found  between 
TNF-α and osteoprotegerin.
Conclusions: The present study indicated that TNF-α and 
BMD was negatively correlated with each other and TNF-α 
had an effect on osteoporotic process in patients with BD. 
Osteoprotegerin level was not decreased, and not correlated 
with TNF-α.
Key words: Behçet’s disease, osteoprotegerin, TNF-α, os-
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INTRODUCTION
Behçet’s disease (BD) is a chronic disease with re-
missions and exacerbations, involving all types of 
blood vessels. It is multi-systemic and multi-organ 
involvement  disease.1  In  several  studies,  it  was 
shown that bone involvement, particularly osteopo-
rosis and osteopenia, is commonly developed in BD 
due to natural course of disease and agents used for 
its treatment.2,3
Osteoporosis is considered to be an imbalance 
of the remodeling process, in which bone resorption 
exceeds bone formation. A growing understanding 
of this process has shown that factors involved in 
inflammation are linked to critical factors associ-
ated with bone physiology. Elevated levels of tumor 
necrosis factor α (TNF- α), interleukine-1 (IL-1), 
interleukine-6  (IL-6)  and  interleukine-18  (IL-18) 
have been found to be critical role in bone and ar-
ticular pathology. All of them play important role in 
induction of bone resorption, resulting in decrease 
in bone mineral density (BMD).4 Osteoprotegerin, 
a member of TNF receptor super-family, is a glyco-
protein which has desired efficacy on bone mineral 
density and metabolism by inhibiting osteoclastic 
activity and formation.3,5
Correlation  between  osteoprotegerin  and  cy-
tokines such as TNF-α and interleukins in BD has 
not been extremely investigated before. In medical 
literature, this is unique study about osteoprotegerin 
and its relation with TNF-α on BMD in patients 
with BD. The purpose of the present study was to 
evaluate bone mineral density in BD, which is more 
commonly seen in our country compared to other 
countries, and to investigate the correlation between 
osteoprotegerin and TNF-α in osteoblastic and os-
teoclastic activity. We also aimed to evaluate osteo-
calcin, deoxypyridinoline and TNF-α level in BD.
MATERIALS AND METHODS 
Study population
The study and control groups were established in the 
study. Forty one BD patients who were diagnosed 
according to the International Study Group criteria 
and admitted to out-patient clinic of rheumatology 
were included in the study. All of the patients suf-
fered from mild to moderate BD, and none of them 
had central nervous system or gastrointestinal in-
volvement, pulmonary lesions or vasculitis. Con-
trol  group  was  selected  as  aged-matched  healthy 
individuals. Age, height and weight of all subjects 
were recorded and body mass index (BMI) was cal-
culated as weight (kg)/height (m2). The study was 
conducted by Suleyman Demirel University Hospi-
tal within 6-months period. An inclusion criterion 
was a previous diagnosis of BD. All participitants 
signed informed consent form before taking part in 
the study. Exclusion criteria were existence of one 
of  the  those  diseases:  thyroidal  diseases  such  as 
hypo and hyperthyroidism, parathyroidism, vitamin 
D  deficiency,  known  post-menopausal  and  senile 
osteoporosis, history of steroid use over 3 months 
or current steroid usage, other immunosuppressant 
treatment  such  as  anti-  TNF-α  antibody  therapy, 
drugs which could affect bone metabolism, diabetes 
mellitus, chronic liver and kidney diseases, men-
strual irregularity, and pregnancy. 
Biochemical analysis
In both groups, TNF-α, osteoprotegerin (OPG), os-
teocalcine, thyroid function tests, total testosterone, 
calcium, phosphorus, ALP, erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), urea, cre-
atinine, fasting glucose, triglyceride, total cholester-
ol, HDL-cholesterol, ALT, AST levels were assayed 
in the morning time after an overnight fasting. Uri-
nary creatinine and deoxypyridinoline levels were 
also assayed at urinary sample that was collected in 
the morning. 
Samples were stored at -70º prior to analysis. 
They were assayed with photometric method using 
biochemistry auto-analyzer (Aerroset, Abbot, Illi-
nois, USA). Total testosterone and thyroid function 
tests were measued with method of chemilumines-
cent immunometric assay (Architech I 2000 Abbot 
Illinois,  USA).  Serum  osteocalcin  was  measured 
with  immunometric  assay  (Immulite  Osteocalcin, 
USA). Urinary deoxypyridinoline (adjusted for cre-
atinine excretion) was measured by a solid phase 
chemiluminescent  enzyme-labeled  immunoassay 
(Immulite  Pyrilinks-D,  USA).  Urinary  creatinine 
and calcium were assayed with modular P 800 Roche 
auto-analyzer. CRP level was assayed with nephelo-
metric method. ESH was measured in a vacutainer 
sedimentation tube with Westerngreen method, us-
ing the Greiner Labr-Austria device. TNF-α levels 
were measured with human TNF-α ELISA kit of 
Biosource International. OPG (BioVendor Labora-
tory Medicine, Czech Republic) levels were mea-A. Kutlucan et al. Behçet’s disease 327
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sured by commercially available ELISA method ac-
cording to the manufacturer’s instructions.
Bone mineral density measurements
Bone mineral density at the lumbar spine and hip 
(femoral neck, Ward’s triangle and trochanter) was 
evaluated by dual x-ray absorptiometry using Nor-
land-XR 2000. The instrument was calibrated daily 
according to the manufacturer’s instructions. BMD 
data were expressed as grams per centimeter square 
and standard deviation scores, and compared with 
BMD values of controls. Osteoporosis and osteo-
penia were defined by using criteria described by 
WHO and the International Osteoporosis Founda-
tion.6
Statistical analysis
Data were analyzed using SPSS version 15.0 (Chi-
cago, IL). Numeric variables were stated as mean ± 
standard deviation. Categorical variables were stat-
ed as frequency and percentage. Variables of inde-
pendent two groups with normal distribution were 
analyzed  with  student’s  t-test,  but  nonparametric 
Kruskal-Wallis H test was used for variables of in-
dependent two groups without normal distribution. 
Correlation between variables with normal distribu-
tion was analyzed with Pearson’s correlation analy-
sis. Spearmen’s correlation analysis was used for 
variables without normal distribution. p<0.05 was 
accepted for statistical significance.
RESULTS
The study enrolled 41 patients with Behçet’s dis-
ease (male=20 and female=21) in the study group 
and 36 aged-matched healthy individuals (male=16 
and female=20) in control group (p>0.05). Mean 
age of participants in the study and control groups 
were  42.26±11.64  years  and  41.66±70.99  years, 
respectively (p>0.05). Mean BMI was 26.11±3.18 
for  the  study  group  and  25.61±3.24  for  controls 
(p>0.005). Mean duration of disease was 5.72±6.15 
years (range 1-28). All participants’ complete blood 
count and biochemical parameters were tested and 
shown in Table 1. There were no significant differ-
ences between two groups, regarding biochemical 
parameters. ESR in the study group was observed 
higher, but difference between two groups didn’t 
reach statistically significant level (18.31±15.84 m/
hr and 14.10±11.43 m/hr, respectively; p=0.190). 
Mean CRP level was found to be statistically signif-
icant higher in the study group, compared to control 
group (15.42±33.03 mg/dl versus 4.52±3.95 mg/dl, 
respectively; p<0.001) (Table 1). 
Table 1. Comparison of basic biochemical and complete 
blood count parameters between study and control group
Study Group Control Group P
ESR (mm/h) 18.31±15.84 14.10±11.43 NS
CRP (mg/L) 15.42±33.03 4.52±3.95 <0.05
ALP (U/L) 235.14±106.99 201.38±50.62 NS
Calcium (mg/dL) 9.64±0.49 9.87±0.38 NS
Phosphor (mg/dL) 3.51±0.62 3.58±0.61 NS
ALT (U/L) 28.21±16.68 22.02±6.90 NS
Hemoglobin (g/dL) 13.8±1.8 13.9±1.4 NS
Hematocrit (%) 39.6±4.9 40.0±3.9 NS
Body Mass Index
(kg/m2)
26.11±3.18 25.61±3.24 NS
ESR:  Erythrocyte  sedimentation  rate,  CRP-C:  reactive 
protein, ALT: alanine transaminase, NS: not significant
In Table 2, levels of TNF-α, osteocalcine, de-
oxypyridinoline,  osteoprotegerin,  urinary  calcium 
and  deoxypyridinoline/urinary  creatinine  ratio  of 
subjects in the study and control group was shown. 
TNF-α (1.94±1.40 pg/ml versus 0.90±0.68 pg/ml, 
p<0.001),  deoxypyridinoline  (8.54±3.12  pmol/L 
versus  4.63±0.48  pmol/L,  p<0.001)  and  osteo-
calcine  (32.02±44.60  ng/ml;  19.91±9.05  ng/ml, 
p=0.041) was found to be statistically significant 
higher in the study group. Although osteoprotegerin 
level was detected as lower in patients with BD, 
it wasn’t found statistically significant (8.66±1.70 
pmol/L versus 9.05±1.85 pmol/L, p>0.05). Urinary 
deoxypyridinoline/urinary  creatinine  ratio  in  pa-
tients with BD compared to control group was found 
to  be  statistically  significant  higher  (0.14±0.30 
nmol/mmol versus 0.05±0.26 nmol/mmol, p=0.03); 
but spot urinary calcium level wasn’t found signifi-
cantly higher in the study group (10.20±8.85 mg/dl 
versus 11.88±10.41 mg/dl, p>0.05).
In Table 3, femur neck T and Z score, vertebra 
(L1-L4) T and Z score, femur neck, great trochlear, 
Wards’ triangle and L2-L4 vertebral BMD according 
to the study and control group were shown. When 
BMD measurement of all subjects was evaluated, 
all parameters in patients with BD were observed 
statistically  significant  lower  than  control  group, 
except  L2-L4  vertebral  area  (p<0.001,  p<0.001, A. Kutlucan et al. Behçet’s disease 328
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p=0.035, p<0.001, p=0.012, p<0.001, p<0.001 and 
p=0.111, respectively). 
Correlation  of  TNF-α  with  osteoprotegerin, 
deoxypyridinoline  level  and  BMD  measurements 
in patients with BD was shown. No any significant 
correlation was observed between TNF-α and oth-
ers (Table 4). 
Table 2.  Comparison  of  bone  turnover  markers  and 
TNF-α between study and control group
Study Group
(n=41)
Control Group
(n=36) P
Osteocalcine (ng/mL) 32.02±44.60 19.91±9.05 0.041
Osteoprotegerin (pmol/L) 8.66±1.70 9.05±1.85 NS
Deoxypyridinoline
 (nmol) 8.54±3.12 4.63±1.48 <0.001
(TNF-α)(pg/mL) 1.94±1.40 0.90±0.68 <0.001
Urinary Deoxypyridinoline/Cr
 (nmol/mmol) 0.14±0.30 0.05±0.26 0.032
Spot Urinary Ca Excretion 
(mg/dL) 10.20±8.85 11.88±10.41 NS
TNF-α: Tumor necrosis factor-alpha; NS: not significant
Table 3.  Comparison  of  bone  mass  density  measure-
ments between study and control group
Study Group
(n=41)
Control Group
(n=36) P
Femur neck T score -0.89±1.32 0.10±0.70 <0.001
Z score -0.35±0.97 0.70±0.73 0.01
Vertebra (L1-L4) T score -0.87±1.25 0.08±0.68 0.035
Z score -0.56±1.15 0.05±0.69 <0.001
Femur neck BMD (gr/cm2) 0.84±0.13 0.90±0.08 0.012
Trochanter BMD (gr/cm2) 0.69±0.11 0.85±0.06 <0.001
Wards BMD (gr/cm2) 0.65±0.13 0.83±0.05 <0.001
L2-L4 BMD (gr/cm2) 0.98±0.16 1.04±0.11 0.111
L: lumbar vertebra, BMD: Bone mineral density
Table 4. Correlation of TNF-α with measurements of bone 
mass density and bone turnover markers of deoxypyridi-
noline and osteoprotegerin
TNF- α
r p
Deoxypyridinoline -0.257 0.104
Osteoprotegerin 0.194 0.224
Femur T score -0.75 0.275
Femur Z score -0.14 0.929
Vertebra T score -0.180 0.260
Vertebra T score -0.018 0.911
Femur neck BMD -0.070 0.666
Trochanter BMD -0.170 0.287
Wards BMD -0.142 0.377
L2-L4 BMD -0.109 0.479
BMD: Bone mineral density
DISCUSSION
In the present study, we investigated osteoproteger-
in activity and it’s relation with TNF-α in BD. Os-
teoprotegerin which is an indicator for osteoblastic 
activity, was found to be reduced in patients with 
BD compared to healthy individuals, but reduction 
wasn’t statistically significant. We also found cor-
relations between TNF-α and bone mineral density 
measurement in the study group.
As a result of causal or a final stage of BD, bone 
breakdown is inevitable when untreated properly. 
Natural course of BD, drugs used in its treatment, 
cytokines which play role in its etiopathogenesis 
may all lead to osteoporosis. Osteoporosis is a re-
sult of disequilibrium between bone formation and 
breakdown. For bone remodeling, equilibrium can 
be provided by interaction between osteoclasts, os-
teoblasts, bone marrow stromal cells and fibroblasts, 
macrophages and T-lymphocytes.3 The relationship 
between BD and osteoporosis has not been studied 
intensively  before  but  there  are  many  studies  on 
other rheumatic diseases such as familial Mediter-
ranean fever and rheumatoid arthritis, which have 
similar etiopathogenesis with BD.7
Behçet’s disease is a chronic and complex dis-
order.  Many  organs  can  be  involved.  During  its 
natural course many cytokines such as IL-1, IL-6 
and TNF-α are secreted into circulation. These are 
known as the most powerful stimulators for bone 
breakdown. TNF-α is one the stimulators known as 
the most potent. Many studies have shown that it is 
effective in bone breakdown.3,8,9 Evereklioglu et al. 
studied IL-1 and TNF-α and found IL-1 levels low 
in patient and control group, whereas, TNF level 
significantly elevated in patients with BD.10 In our 
study, we studied only TNF-α and found TNF-α lev-
el lower in the case group compared to the healthy 
control group, similar to the former study. Osteo-
calcin is biological marker indicating bone forma-
tion process and relatively well correlated with in-
crease in bone mineral density. In several studies, 
on rheumatoid diseases, osteocalcin level was found 
to be decreased. Gursoy et al. studied on relation 
between rheumatoid arthritis and osteocalcin along 
with bone mineral density.11 They found osteocalcin 
level higher in patient group compared with con-
trol group. On the other hand, Kirnap et al. stud-
ied relation between cytokines and BD, and found 
no correlation between osteocalcin and cytokines.3 A. Kutlucan et al. Behçet’s disease 329
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However, we found osteocalcin level significantly 
higher and a weak positive correlation between os-
teocalcin and TNF-α in patients with BD, indicating 
increased bone turnover. 
Deoxypyridinoline is a degradation product of 
collagen in the urine, and has been used as marker 
in the diagnosis and follow-up of osteoporosis. It 
has been found to be a sensitive and specific marker 
indicating bone resorption.12,13 Urinary deoxypyrid-
inoline hasn’t been intensively studied on osteopo-
rosis in patients with BD. Tekin et al. studied bone 
turnover  markers  of  patients  with  BD,  including 
osteocalcin, urinary deoxypyridinoline and BMD. 
They found no significant differences between pa-
tient and control group.4 Kirnap et al. studied bone 
markers in patients with BD and also found no sig-
nificant difference.3 However, we found significant 
difference in urinary deoxypyridinoline level and 
urinary  deoxypyridinoline/urinary  creatinine  be-
tween normal controls and patients with BD. This 
result might be due to our study design and patients’ 
clinics, because deoxypyridinoline could be affected 
by inflammatory state of natural course of disease.
Majority of the patients were above level of os-
teoporotic and osteopenic value defined by WHO.14,15 
In the present study, on the other hand, T and Z 
scores of femur and vertebra in patients with BD 
were significantly lower than control group. BMD 
measurements of femur neck, Trochlear and Wards’ 
triangle except L2-L4 spine in the study group were 
significantly lower, compared with control group. 
It indicated that bone resorption increased in our 
patients. Bicer et al. found and reported no signifi-
cant differences between control and BD patients.2 
Kirnap et al. reported significant difference in bone 
mineral density, T score and scores of L2-L4, but 
not in other region.3 We found significant difference 
in all regions of BMD measurements except L2-L4 
vertebra BMD. 
Cytokines  such  as  TNF-α  have  osteoporotic 
effect on bony structure, increasing bone turnover. 
In several studies, it was shown that cytokines such 
as  IL-1  and  TNF-α  increased  bone  resorption  in 
rheumatologic diseases. However, there are a few 
studies on correlation between bone mineral density 
and cytokines in BD. Osteoporotic process due to 
cytokines such as TNF-α and interleukins in the BD 
has not been extremely investigated before. There 
are a few studies in the literature. Particularly, they 
are from Turkey. Akdeniz et al. reported that serum 
levels of IL-2, IL-6, TNF-α, and nitric oxide con-
centrations in patients with BD were found to be 
statistically  significant  higher  than  controls.16  We 
found non-significant negative correlation between 
TNF-α and bone mineral density measurements.
Osteoprotegerin is a basic glycoprotein and cy-
tokine receptor, belonging to tumor necrosis factor 
super family member. It can reduce the production of 
osteoclasts by inhibiting osteoclasts differentiation. 
It specifically acts on bone, increasing bone mineral 
density and bone volume.17,18 In an experimental an-
imal study conducted by Schett et al., it was shown 
that bone resorption induced by increased TNF-α 
could be inhibited by osteoprotegerin.5 In the pres-
ent study, we studied on osteoprotegerin level and 
correlation between TNF-α and osteoprotegerin. We 
found that osteoprotegerin level was increased in 
our patients, but it didn’t reach statistically signifi-
cant level compared to control group. We expect-
ed that osteoprotegerin would be decreased under 
TNF-α secretion, so we would have suggested anti-
TNF-α treatment in patients with BD to increase os-
teoprotegerin. However, osteoprotegerin level has 
not been decreased while TNF-α increased. It might 
be due to compensation mechanism respect to TNF-
α-induced bone turnover. 
There are some limitations and highlights for 
our study. Some reports also suggested that duration 
of  chronic  diseases  is  negatively  associated  with 
BMD at site in patients with rheumatoid arthritis.19 
However, studies didn’t found any association be-
tween BMD and BD. In the present study, we didn’t 
investigate correlation or association between dura-
tion of disease and BMD. In prospective studies, 
the course of the disease and treatment effects on 
disease along the time can be followed up and some 
outcomes can be obtained. But, as our study was de-
signed as cross-sectional, we could not observe any 
prognostic features or treatment effects on course of 
BD. Sample size of this study was relatively small. 
Further studies with larger sample in size are need-
ed for more confidential and rational results. 
Highlights of the present study can be stated 
as factors such as age, BMI and sex, which can 
cause osteoporosis, were excluded. Isolated effect 
of TNF-α on bone turnover was evaluated. This is 
the first study which evaluated correlation between 
osteoprotegerin and TNF-α in BD.A. Kutlucan et al. Behçet’s disease 330
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In  conclusion,  the  study  indicated  that  bone 
turnover  and  TNF-α  levels  increased  in  patients 
with BD and also it was shown that TNF-α and 
BMD  were  negatively  correlated.  We  concluded 
that TNF-α had an effect on osteoporotic process in 
patients with BD. 
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